874 related articles for article (PubMed ID: 11118018)
1. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique.
Scholtz HE; Pretorius SG; Wessels DH; Becker RH
Diabetologia; 2005 Oct; 48(10):1988-95. PubMed ID: 16160867
[TBL] [Abstract][Full Text] [Related]
3. Fluctuation of serum basal insulin levels following single and multiple dosing of insulin glargine.
Gerich J; Becker RH; Zhu R; Bolli GB
Diabetes Technol Ther; 2006 Apr; 8(2):237-43. PubMed ID: 16734552
[TBL] [Abstract][Full Text] [Related]
4. Clinical strategies for controlling peaks and valleys: type 1 diabetes.
Bolli GB
Int J Clin Pract Suppl; 2002 Jul; (129):65-74. PubMed ID: 12166610
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.
Owens DR; Coates PA; Luzio SD; Tinbergen JP; Kurzhals R
Diabetes Care; 2000 Jun; 23(6):813-9. PubMed ID: 10841002
[TBL] [Abstract][Full Text] [Related]
6. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
Rosenstock J; Park G; Zimmerman J;
Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511
[TBL] [Abstract][Full Text] [Related]
7. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study.
Lucidi P; Porcellati F; Rossetti P; Candeloro P; Cioli P; Marzotti S; Andreoli AM; Fede R; Bolli GB; Fanelli CG
Diabetes Care; 2011 Jun; 34(6):1312-4. PubMed ID: 21498786
[TBL] [Abstract][Full Text] [Related]
9. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.
Plank J; Bodenlenz M; Sinner F; Magnes C; Görzer E; Regittnig W; Endahl LA; Draeger E; Zdravkovic M; Pieber TR
Diabetes Care; 2005 May; 28(5):1107-12. PubMed ID: 15855574
[TBL] [Abstract][Full Text] [Related]
10. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study.
Bolli GB; Kerr D; Thomas R; Torlone E; Sola-Gazagnes A; Vitacolonna E; Selam JL; Home PD
Diabetes Care; 2009 Jul; 32(7):1170-6. PubMed ID: 19389820
[TBL] [Abstract][Full Text] [Related]
11. Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes.
Linn T; Fischer B; Soydan N; Eckhard M; Ehl J; Kunz C; Bretzel RG
J Clin Endocrinol Metab; 2008 Oct; 93(10):3839-46. PubMed ID: 18611975
[TBL] [Abstract][Full Text] [Related]
12. The action profile of lispro is not blunted by mixing in the syringe with NPH insulin.
Joseph SE; Korzon-Burakowska A; Woodworth JR; Evans M; Hopkins D; Janes JM; Amiel SA
Diabetes Care; 1998 Dec; 21(12):2098-102. PubMed ID: 9839100
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection.
Lucidi P; Porcellati F; Marinelli Andreoli A; Carriero I; Candeloro P; Cioli P; Bolli GB; Fanelli CG
Diabetes Care; 2015 Dec; 38(12):2204-10. PubMed ID: 26358287
[TBL] [Abstract][Full Text] [Related]
14. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens.
Murphy NP; Keane SM; Ong KK; Ford-Adams M; Edge JA; Acerini CL; Dunger DB
Diabetes Care; 2003 Mar; 26(3):799-804. PubMed ID: 12610040
[TBL] [Abstract][Full Text] [Related]
15. Early morning glycaemia and the metabolic consequences of delaying breakfast/morning insulin. A comparison of continuous subcutaneous insulin infusion and multiple injection therapy with human isophane or human ultralente insulin at bedtime in insulin-dependent diabetics.
Haakens K; Hanssen KF; Dahl-Jørgensen K; Vaaler S; Torjesen P; Try K
Scand J Clin Lab Invest; 1989 Nov; 49(7):653-9. PubMed ID: 2692136
[TBL] [Abstract][Full Text] [Related]
16. Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes.
Bolli GB; Songini M; Trovati M; Del Prato S; Ghirlanda G; Cordera R; Trevisan R; Riccardi G; Noacco C
Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):571-9. PubMed ID: 18676131
[TBL] [Abstract][Full Text] [Related]
17. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.
Raskin P; Klaff L; Bergenstal R; Hallé JP; Donley D; Mecca T
Diabetes Care; 2000 Nov; 23(11):1666-71. PubMed ID: 11092290
[TBL] [Abstract][Full Text] [Related]
18. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
Heise T; Nosek L; Rønn BB; Endahl L; Heinemann L; Kapitza C; Draeger E
Diabetes; 2004 Jun; 53(6):1614-20. PubMed ID: 15161770
[TBL] [Abstract][Full Text] [Related]
19. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.
Heinemann L; Linkeschova R; Rave K; Hompesch B; Sedlak M; Heise T
Diabetes Care; 2000 May; 23(5):644-9. PubMed ID: 10834424
[TBL] [Abstract][Full Text] [Related]
20. Short-term effects of NPH insulin, insulin detemir, and insulin glargine on the GH-IGF1-IGFBP axis in patients with type 1 diabetes.
Ma Z; Christiansen JS; Laursen T; Lauritzen T; Frystyk J
Eur J Endocrinol; 2014 Oct; 171(4):471-9. PubMed ID: 25005937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
